cabozantinib,ramucirumab,atezolizumab,pembrolizumab
eli lilly,exelixis,merck,roche
['lcsm,(-blcsm)', 's1800a', 'sclc', 'nsclc', 'cosmic-021']
based on cosmic-021 &amp; s1800a data, are you in favor of continued t/t with io beyond progression in stage iv nsclc? (while acknowledging the fact that we need a phase-3 trial) #lcsm #asco22 
Assistant Prof | Thoracic Oncology & Phase-I  @karmanoscancer | Previously @MayoCancerCare @gundersenhealth @JeffHealthAb @bpkihsofficial | Views/Tweets my own